OH-UWL
26.4.2022 19:42:09 CEST | Business Wire | Press release
UWL, a top 10 American-owned NVOCC and leading provider of global 3PL services, has contracted with Swire Shipping, a multi-purpose liner service, to launch a new, exclusive express service, departing from Ho Chi Minh City and arriving at the Port of Seattle in 18 days. Providing speed and predictability, the bi-weekly service offers the fastest trip from Vietnam to the US. This revolutionary agreement is the first dedicated ocean service by an NVOCC in the trade.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220426006070/en/
“Customers have been asking for creative solutions during this extremely challenging market, and this first-of-its-kind service is part of our response. Congestion and rate spikes will come and go, but the root issues remain. US importers are pushing for more creativity and controlled reliable solutions to manage supply chain risk,” UWL President Duncan Wright said.
The service offers priority berthing at both origin and destination, and a dedicated equipment pool for suppliers in Ho Chi Minh City. This includes 6,000 brand-new ocean containers, with 40-foot-high cube and 20-foot containers already in the rotation. Predictability is assured, as schedules are published six months in advance, with two sailings per month.
Upon arrival in Seattle, those needing warehousing or distribution space can take advantage of UWL’s sister company, World Distribution Services (WDS), and its brand-new 300,000 sq. ft. facility near Tacoma, WA, just a short drive away from the Port of Seattle.
“In joining forces with UWL, an innovative and integrated logistics provider to American BCOs, we are confident that our ocean express solution will be compelling to importers and exporters who need a direct port-to-port, fast, and reliable service between Vietnam and the Pacific Northwest,” said Rufus Frere-Smith, Regional Head, Americas, Swire Shipping, which facilitates trade in more than 90 countries and across 400 ports. “Our partnership is built on a joint vision of responding to customers’ desire for reliable, safe, and innovative shipping solutions.”
Mr. Wright noted: “We have seen incredibly strong demand for this service already, which tells us that fast and reliable niche services are here to stay. Our relationship with Swire Shipping is critical to making all this work. Their remarkable 150-year history and robust knowledge of ocean shipping and strong Asia legacy, combined with UWL’s culture of innovation, brings this dedicated service to life.”
Mr. Frere-Smith commented: “We have deployed new state-of-the-art, fuel-efficient vessels that will sail at high speed, safely and sustainably. We are confident customers and BCOs will find this direct, express service to be extremely effective in shipping their high value products and getting to market quickly.”
About UWL
UWL is a top 10 American-owned NVOCC and leading provider of global 3PL services. They take pride in delivering seamless supply chain solutions backed by a team of creative problem-solvers. Specializing in ocean transportation, air freight, road and rail, warehousing and distribution, project cargo, and customs house brokerage, their proof is in owned assets: a national network of distribution centers, dependable trucking capacity, and WorldScope , a user-friendly data management platform that delivers transparency and visibility customers can count on. Wherever your freight needs to go, they can help get it there. To find out more, visit their website at www.shipuwl.com
About Swire Shipping
Swire Shipping is a privately owned organization that was founded in 1872 and now comprises over 600 employees in 20 countries and owns and deploys over 30 vessels in the intra-Asia, Australasia, and Polynesia trades. It is part of the Swire Group which is a Hong Kong- and London-based British conglomerate. Many of its core businesses can be found within the Asia Pacific region, where traditionally Swire’s operations have centered on Hong Kong and mainland China. Its subsidiaries include Cathay Pacific Airlines, Swire Properties, China Navigation Company, Swire Hotels and Swire Resources.
About World Group
World Group was founded over 60 years ago as a pioneer in vessel agency services on the Great Lakes. Today, they are home to a portfolio of globally trusted brands that deliver customers end-to-end supply chain and logistics solutions, including ContainerPort Group, UWL, World Distribution Services, and World Shipping, Inc. With industry-leading products in ocean drayage and domestic trucking, freight forwarding and air freight, customs house brokerage, vessel husbandry, and warehousing and distribution, customers around the globe use their services to simplify supply chains and reliably move freight.
Offering career opportunities across the country for innovators in the transportation industry, their award-winning culture is anchored in people who live and breathe the company’s core values daily. Learn how to join the World Group family by visiting their careers page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426006070/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom